Bengal Physician Journal

Register      Login

VOLUME 6 , ISSUE 2 ( May-August, 2019 ) > List of Articles

UPDATE ARTICLE

What is New in Systemic Lupus Erythematosus: A 2019–2020 Update

Rathindranath Sarkar

Keywords : Interferonopathy, Steroids, Systemic lupus erythematosus, TREX-1,ACR/EULAR

Citation Information : Sarkar R. What is New in Systemic Lupus Erythematosus: A 2019–2020 Update. Bengal Physician Journal 2019; 6 (2):40-44.

DOI: 10.5005/jp-journals-10070-6113

License: CC BY-NC 4.0

Published Online: 00-08-2019

Copyright Statement:  Copyright © 2019; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Scientific understanding of systemic lupus erythematosus (SLE) is progressing at a steady pace. Thus, there has been a paradigm shift in the understanding of the pathogenesis of SLE. As clinical experience of SLE is accumulating, the criteria for diagnosis are also being modified. Treatment of SLE still leaves a lot to be desired but every year, there are new additions and alterations. This article sums up these recent changes, especially those in the management of SLE.


PDF Share
  1. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78(6):736–745. DOI: 10.1136/annrheumdis-2019-215089.
  2. Ruiz-Irastorza G, Garcia M, Espinosa G, et al. First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. Lupus Sci Med 2016;3(1):e000153. DOI: 10.1136/lupus-2016- 000153.
  3. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73(6):958–967. DOI: 10.1136/annrheumdis-2013-205139.
  4. Piga M, Floris A, Cappellazzo G, et al. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis Res Ther 2017;19(1):247. DOI: 10.1186/s13075-017-1451-5.
  5. Crow MK, Ronnblom L. Type I interferons in host defense and inflammatory diseases. Lupus Sci Med 2019;6(1):e000336. DOI: 10.1136/lupus-2019-000336.
  6. Banchereau R, Hong S, Cantarel B, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 2016;165(3):551–565. DOI: 10.1016/j.cell.2016.03.008.
  7. Hagberg N, Joelsson M, Leonard D, et al. The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE. Ann Rheum Dis 2018;77(7): 1070–1077. DOI: 10.1136/annrheumdis-2017-212794.
  8. Alerin JM, Ortiz-Fernández L, Sawalha AH. Monogenic lupus: a developing paradigm of disease. Front Immunol 2018;9:2496. DOI: 10.3389/fimmu.2018.02496.
  9. Rice GI, Rodero MP, Crow YJ. Human disease phenotypes associated with mutations in TREX1. J Clin Immunol 2015;35(3):235–243. DOI: 10.1007/s10875-015-0147-3.
  10. Hagberg N, Rönnblom L. Systemic lupus erythematosus—a disease with a dysregulated type I interferon system. Scand J Immunol 2015;82(3):199–207. DOI: 10.1111/sji.12330.
  11. Macedo ACL, Isaac L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front Immunol 2016;7:55. DOI: 10.3389/fimmu.2016.00055.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.